Company GTx, Inc. Nasdaq

Equities

US40052B2079

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Companyâs product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.

USD in Million	2022	Weight	2023	Weight	Delta
Novel Oncology Therapies 100.0 %	1	100.0 %	1	100.0 %	-47.32%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	1	100.0 %	1	100.0 %	-47.32%

Managers	Title	Age	Since
James Breitmeyer FOU	Founder	70	01/97/01
Richard Vincent DFI	Director of Finance/CFO	61	01/17/01
Salim Yazji CTO	Chief Tech/Sci/R&D Officer	55	17/21/17
Rajesh Krishnan CTO	Chief Tech/Sci/R&D Officer	51	28/19/28
Pablo Urbaneja PRN	Corporate Officer/Principal	-	01/21/01
Anita Wiseth HRO	Human Resources Officer	-	01/21/01
Chase Leavitt LAW	General Counsel	42	12/21/12

Members of the board	Title	Age	Since
David Hale FOU	Founder	75	01/97/01
Dan Kisner BRD	Director/Board Member	77	07/19/07
Rosemary Mazanet BRD	Director/Board Member	67	27/21/27
James Breitmeyer FOU	Founder	70	01/97/01
William LaRue BRD	Director/Board Member	73	01/17/01
Michael Carter BRD	Director/Board Member	86	07/19/07
Charles Theuer BRD	Director/Board Member	60	01/18/01
Jill DeSimone BRD	Director/Board Member	68	03/23/03
Robert Wills BRD	Director/Board Member	70	07/19/07
Xin Nakanishi BRD	Director/Board Member	62	01/18/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,959,645	2,686,463 ( 90.77 %)	0	90.77 %

Name	Equities	%	Valuation
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD 5.988 %	177,222	5.988 %	2 M $
Vanguard Global Advisers LLC 4.833 %	143,045	4.833 %	1 M $
Millennium Management LLC 3.473 %	102,795	3.473 %	925 155 $
BlackRock Institutional Trust Co. NA 1.327 %	39,285	1.327 %	353 565 $
James Breitmeyer 1.108 %	32,787	1.108 %	295 083 $
Hale BioPharma Ventures LLC 1.003 %	29,673	1.003 %	267 057 $
Richmond Brothers, Inc. 0.8346 %	24,702	0.8346 %	222 318 $
BIT Capital GmbH 0.7045 %	20,850	0.7045 %	187 650 $
Renaissance Technologies LLC 0.5528 %	16,360	0.5528 %	147 240 $
Robert Wills 0.3379 %	10,000	0.3379 %	90 000 $

Oncternal Therapeutics, Inc.

12230 El Camino Real Suite 230

92130, San Diego

http://www.oncternal.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+21.74%	46.81B
IQVIA HOLDINGS INC.	-0.97%	41.37B
LONZA GROUP AG	+47.07%	41.29B
CELLTRION, INC.	-3.52%	28.87B
ICON PUBLIC LIMITED COMPANY	+11.12%	26.06B
ALNYLAM PHARMACEUTICALS, INC.	-19.37%	19.13B
MEDPACE HOLDINGS, INC.	+31.18%	12.39B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.04%	12.08B
BIO-TECHNE CORPORATION	+0.39%	11.96B

Other Biotechnology & Medical Research